NCT04171843View on ClinicalTrials.gov

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

October 19, 2022

Study Completion Date

October 19, 2022

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
GENETIC

PBCAR269A

Allogeneic anti-BCMA CAR T-cell

DRUG

Fludarabine

Fludarabine is used for lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion.

DRUG

Nirogacestat

Allogeneic anti-BCMA CAR T-cell

Trial Locations (5)

10032

Columbia University Irving Medical Center, New York

77030

MD Anderson, Houston

91010

City of Hope, Duarte

94115

University of California San Francisco, San Francisco

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Precision BioSciences, Inc.

INDUSTRY

NCT04171843 - A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter